-
Mashup Score: 22From No Hope to a Potential Cure for a Deadly Blood Cancer - 1 month(s) ago
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.
Source: www.nytimes.comCategories: General Medicine NewsTweet
-
Mashup Score: 24Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? - 2 month(s) ago
The pivotal work by Shi et al 1 supports the role of minimal residual disease (MRD) in accelerating drug approvals, advancing precision medicine, and reshaping clinical trial design to better tailor therapies and with the final aim of improving patient care. In the article that accompanies this editorial, Shi et al 1 present compelling evidence supporting the use of minimal residual disease negativity in complete response as an intermediate end point for predicting survival outcomes in multiple myeloma.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Great Editorial by Marivi Mateos and Noemi Puig on Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? | Journal of Clinical Oncology https://t.co/WW1yosbKSZ
-
-
Mashup Score: 17Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? - 3 month(s) ago
The pivotal work by Shi et al 1 supports the role of minimal residual disease (MRD) in accelerating drug approvals, advancing precision medicine, and reshaping clinical trial design to better tailor therapies and with the final aim of improving patient care. In the article that accompanies this editorial, Shi et al 1 present compelling evidence supporting the use of minimal residual disease negativity in complete response as an intermediate end point for predicting survival outcomes in multiple myeloma.
Source: ascopubs.orgCategories: General Medicine NewsTweet-
Great Editorial by Marivi Mateos and Noemi Puig on Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point? | Journal of Clinical Oncology https://t.co/WW1yosbKSZ
-
-
Mashup Score: 46Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy - 7 month(s) ago
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@rajshekharucms 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy https://t.co/LUoYRtpapZ
-
-
Mashup Score: 7Michel Sadelain Appointed Inaugural Director of the Columbia Initiative in Cell Engineering and Therapy | Office of the President - 9 month(s) ago
Dear members of the Columbia community: I am immensel y pleased to announce the appointment of Michel Sadelain, MD, PhD, as the inaugural Director of the Columbia Initiative in Cell Engineering and Therapy (CICET). This new University-wide initiative builds on our existing research into cell and gene therapies and aims to drive greater progress in fundamental and translational science at Columbia. Dr. Sadelain will also serve as the Director of the Medical Center’s Cancer Cell Therapy Initiative in the
Source: president.columbia.eduCategories: General Medicine News, Hem/OncsTweet-
Michel Sadelain Appointed Inaugural Director of the Columbia Initiative in Cell Engineering and Therapy | Office of the President https://t.co/2Mpe782lbL
-
-
Mashup Score: 46Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy - 10 month(s) ago
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@rajshekharucms 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy https://t.co/LUoYRtpapZ
-
-
Mashup Score: 46Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy - 10 month(s) ago
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@rajshekharucms 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy https://t.co/LUoYRtpapZ
-
-
Mashup Score: 44Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy - 10 month(s) ago
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@rajshekharucms 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy https://t.co/LUoYRtpapZ
-
-
Mashup Score: 41Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy - 10 month(s) ago
Key Points. +1q is associated with worse hematologic response rate and event-free survival with daratumumab-based frontline therapy in AL amyloidosist(11;1
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
@rajshekharucms 👍🏻👍🏻Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy https://t.co/LUoYRtpapZ
-
-
Mashup Score: 3
Nature – Cotranslational N-terminal methionine excision and acetylation of eukaryotic proteins on ribosomes is coordinated by the nascent polypeptide-associated complex.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @BMT_updates: Congrats @alfredlentzsch !! @Nature @SLentzsch https://t.co/TXtSmb6lOk
-
Fantastic results! Also today in the @nytimes @PlasmaCellPete @MyelomaRnD https://t.co/8SpESir3Dp https://t.co/Ze2qLF0GZ5